Close Menu

Biocept

Biocept's Target Selector liquid biopsy platform is designed to analyze both circulating tumor cell and circulating tumor DNA biomarkers from a blood sample.

OHSU was granted the rights to offer Biocept's Target Selector liquid biopsy testing services in Oregon as part of the deal. 

The company said it expects to net around $8.4 million, which it will use for working capital and general corporate purposes.

Catalyst will use Biocept's liquid biopsy platform to screen for cancer in patients in a clinical study of its rare disease drug Firdapse.

The company said it accessioned 1,175 total samples during the quarter, up from 663 total samples in Q4 2015.

Ahead of a longer-term goal to develop IVD kits, the company has a plan this year to allow early-access customers to take on one aspect of testing in their own labs.

The firm was able to maintain a minimum closing bid price of at least $1 per share for at least 10 consecutive business days.

Members of the health plan will have access to Biocept's growing menu of circulating tumor cell and circulating tumor DNA tests.

Investigators will compare results using Biocept's platform in cerebrospinal fluid to current standard methods for diagnosing leptomeningeal metastases.

The company said in a filing with the US Securities and Exchange Commission that it failed to maintain compliance with the Nasdaq's minimum closing bid price requirement.

Pages

A new report offers ways for small, society publishers to transition to Plan S standards, ScienceInsider says.

A gas explosion sparked a fire at a Russian laboratory that stores dangerous pathogens, the Guardian reports.

Researchers turn to protein analysis to examine an ancient rhino sample, Smithsonian.com reports.

In PNAS this week: C2CD4A gene involved in insulin secretion, chromosome rearrangements in recurring S. aureus infections, and more.